{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:26:40Z","timestamp":1791505600198,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Source Research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psychedelic compounds have been linked to salutary mental health outcomes in both naturalistic and clinical settings; however, current research on psychedelics suffers from a lack of inclusion and focus on racial and ethnic minorities. Thus, the goal of our study was to assess whether race and ethnicity moderate the associations that naturalistic lifetime MDMA (3,4-Methylenedioxymethamphetamine) use and psilocybin use share with past month psychological distress and past year suicidality (ideation and planning). Using data from the National Survey on Drug Use and Health (NSDUH) (2008\u20132019) (<jats:italic>N<\/jats:italic>\u2009=\u2009484,732), we conducted survey-weighted multivariable logistic regression to conduct interaction tests and to assess the associations that MDMA use and psilocybin use share with the aforementioned outcomes for each racial and ethnic group. Race and ethnicity significantly moderated the associations between MDMA and psilocybin use and psychological distress and suicidality. For White participants, MDMA and psilocybin use conferred lowered odds of all distress and suicidality outcomes. For racial and ethnic minority\u00a0participants, the associations between psychedelic use and suicidality were far fewer. These findings invite further research into the impact of race, ethnicity, and other identity factors (e.g., socioeconomic status, sexual\/gender minority status) on the effects of psychedelic substances.<\/jats:p>","DOI":"10.1038\/s41598-022-18645-3","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T11:58:49Z","timestamp":1665403129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality"],"prefix":"10.1038","volume":"12","author":[{"given":"Grant M.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew K.","family":"Nock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"18645_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths, R. R., Richards, W. A., McCann, U. & Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187, 268\u2013283 (2006).","journal-title":"Psychopharmacology"},{"key":"18645_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41429-020-0311-8","volume":"73","author":"DE Nichols","year":"2020","unstructured":"Nichols, D. E. Psilocybin: From ancient magic to modern medicine. J. Antibiot. 73, 679\u2013686 (2020).","journal-title":"J. Antibiot."},{"key":"18645_CR3","first-page":"1","volume-title":"Handbuch Psychoaktive Substanzen","author":"B Sessa","year":"2016","unstructured":"Sessa, B. The History of Psychedelics in Medicine. In Handbuch Psychoaktive Substanzen (eds von Heyden, M. et al.) 1\u201326 (Springer, 2016)."},{"key":"18645_CR4","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths, R. R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J. Psychopharmacol. 30, 1181\u20131197 (2016).","journal-title":"J. Psychopharmacol."},{"key":"18645_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob, C. S. et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch. Gen. Psychiatry 68, 71 (2011).","journal-title":"Arch. Gen. Psychiatry"},{"key":"18645_CR6","first-page":"1","volume":"2021","author":"JM Mitchell","year":"2021","unstructured":"Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Med. 2021, 1\u20139 (2021).","journal-title":"Nature Med."},{"key":"18645_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/0269881112456611","volume":"27","author":"MC Mithoefer","year":"2013","unstructured":"Mithoefer, M. C. et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. J. Psychopharmacol. 27, 28\u201339 (2013).","journal-title":"J. Psychopharmacol."},{"key":"18645_CR8","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","volume":"236","author":"MC Mithoefer","year":"2019","unstructured":"Mithoefer, M. C. et al. MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology 236, 2735\u20132745 (2019).","journal-title":"Psychopharmacology"},{"key":"18645_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/0269881112464827","volume":"27","author":"P Oehen","year":"2013","unstructured":"Oehen, P., Traber, R., Widmer, V. & Schnyder, U. A randomized, controlled pilot study of MDMA (\u00b13,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J. Psychopharmacol. 27, 40\u201352 (2013).","journal-title":"J. Psychopharmacol."},{"key":"18645_CR10","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1177\/0269881118806297","volume":"32","author":"GM Otalora","year":"2018","unstructured":"Otalora, G. M. et al. 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. J. Psychopharmacol. 32, 1295\u20131307 (2018).","journal-title":"J. Psychopharmacol."},{"key":"18645_CR11","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","volume":"235","author":"AL Danforth","year":"2018","unstructured":"Danforth, A. L. et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: A randomized, double-blind, placebo-controlled pilot study. Psychopharmacology 235, 3137\u20133148 (2018).","journal-title":"Psychopharmacology"},{"key":"18645_CR12","unstructured":"Multidisciplinary Association for Psychedelic Studies (2020) Randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness. clinicaltrials.gov"},{"key":"18645_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz, M. P. et al. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J. Psychopharmacol. 29, 289\u2013299 (2015).","journal-title":"J. Psychopharmacol."},{"key":"18645_CR14","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. & Griffiths, R. R. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J. Psychopharmacol. 28, 983\u2013992 (2014).","journal-title":"J. Psychopharmacol."},{"key":"18645_CR15","first-page":"39235","volume":"83","author":"RJ Zeifman","year":"2022","unstructured":"Zeifman, R. J. et al. Decreases in suicidality following psychedelic therapy: A meta-analysis of individual patient data across clinical trials. J. Clin. Psychiatry 83, 39235 (2022).","journal-title":"J. Clin. Psychiatry"},{"key":"18645_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12888-018-1824-6","volume":"18","author":"TI Michaels","year":"2018","unstructured":"Michaels, T. I., Purdon, J., Collins, A. & Williams, M. T. Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature. BMC Psychiatry 18, 245 (2018).","journal-title":"BMC Psychiatry"},{"key":"18645_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3285","author":"AK Davis","year":"2020","unstructured":"Davis, A. K. et al. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiat. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285 (2020).","journal-title":"JAMA Psychiat."},{"key":"18645_CR18","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris, R. et al. Trial of psilocybin versus escitalopram for depression. N. Engl. J. Med. 384, 1402\u20131411 (2021).","journal-title":"N. Engl. J. Med."},{"key":"18645_CR19","first-page":"1","volume":"2020","author":"MT Williams","year":"2020","unstructured":"Williams, M. T. et al. People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. Drugs Educ. Prevent. Policy 2020, 1\u201312 (2020).","journal-title":"Drugs Educ. Prevent. Policy"},{"key":"18645_CR20","doi-asserted-by":"crossref","first-page":"247054702110356","DOI":"10.1177\/24705470211035607","volume":"5","author":"AK Davis","year":"2021","unstructured":"Davis, A. K., Xin, Y., Sepeda, N. D., Garcia-Romeu, A. & Williams, M. T. Increases in psychological flexibility mediate relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color. Chronic Stress (Thousand Oaks) 5, 24705470211035610 (2021).","journal-title":"Chronic Stress (Thousand Oaks)"},{"key":"18645_CR21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/0269881114565653","volume":"29","author":"PS Hendricks","year":"2015","unstructured":"Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W. & Johnson, M. W. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J. Psychopharmacol. 29, 280\u2013288 (2015).","journal-title":"J. Psychopharmacol."},{"key":"18645_CR22","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3389\/fpsyt.2019.00896","volume":"10","author":"JD Sexton","year":"2020","unstructured":"Sexton, J. D., Nichols, C. D. & Hendricks, P. S. Population survey data informing the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics. Front. Psych. 10, 896 (2020).","journal-title":"Front. Psych."},{"key":"18645_CR23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/02698811211058923","volume":"36","author":"GM Jones","year":"2022","unstructured":"Jones, G. M. & Nock, M. K. MDMA\/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. J. Psychopharmacol. 36, 46\u201356 (2022).","journal-title":"J. Psychopharmacol."},{"key":"18645_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1017\/S0033291702006700","volume":"33","author":"TA Furukawa","year":"2003","unstructured":"Furukawa, T. A., Kessler, R. C., Slade, T. & Andrews, G. The performance of the K6 and K10 screening scales for psychological distress in the Australian National Survey of Mental Health and Well-Being. Psychol. Med. 33, 357\u2013362 (2003).","journal-title":"Psychol. Med."},{"key":"18645_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.annepidem.2008.09.005","volume":"19","author":"LJ Colpe","year":"2009","unstructured":"Colpe, L. J., Epstein, J. F., Barker, P. R. & Gfroerer, J. C. Screening for serious mental illness in the National Survey on Drug Use and Health (NSDUH). Ann. Epidemiol. 19, 210\u2013211 (2009).","journal-title":"Ann. Epidemiol."},{"key":"18645_CR26","first-page":"1","volume":"9","author":"T Lumley","year":"2020","unstructured":"Lumley, T. Survey: Analysis of complex survey samples. J. Stat. Softw. 9, 1\u201319 (2020).","journal-title":"J. Stat. Softw."},{"key":"18645_CR27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1177\/0269881117691453","volume":"31","author":"VD Pisano","year":"2017","unstructured":"Pisano, V. D. et al. The association of psychedelic use and opioid use disorders among illicit users in the United States. J. Psychopharmacol. 31, 606\u2013613 (2017).","journal-title":"J. Psychopharmacol."},{"key":"18645_CR28","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1046\/j.1360-0443.2002.00222.x","volume":"97","author":"JC Cole","year":"2002","unstructured":"Cole, J. C., Bailey, M., Sumnall, H. R., Wagstaff, G. F. & King, L. A. The content of ecstasy tablets: Implications for the study of their long-term effects. Addiction 97, 1531\u20131536 (2002).","journal-title":"Addiction"},{"key":"18645_CR29","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1177\/0269881117715596","volume":"31","author":"S Saleemi","year":"2017","unstructured":"Saleemi, S., Pennybaker, S. J., Wooldridge, M. & Johnson, M. W. Who is \u2018Molly\u2019? MDMA adulterants by product name and the impact of harm-reduction services at raves. J. Psychopharmacol. 31, 1056\u20131060 (2017).","journal-title":"J. Psychopharmacol."},{"key":"18645_CR30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/0022042616678614","volume":"47","author":"A Rosenberg","year":"2017","unstructured":"Rosenberg, A., Groves, A. K. & Blankenship, K. M. Comparing black and white drug offenders: Implications for racial disparities in criminal justice and reentry policy and programming. J. Drug Issues 47, 132\u2013142 (2017).","journal-title":"J. Drug Issues"},{"key":"18645_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/0269881117735685","volume":"32","author":"PS Hendricks","year":"2018","unstructured":"Hendricks, P. S. et al. The relationships of classic psychedelic use with criminal behavior in the United States adult population. J. Psychopharmacol. 32, 37\u201348 (2018).","journal-title":"J. Psychopharmacol."},{"key":"18645_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/02791072.2006.10399838","volume":"38","author":"M Lerner","year":"2006","unstructured":"Lerner, M. & Lyvers, M. Values and beliefs of psychedelic drug users: A cross-cultural study. J. Psychoactive Drugs 38, 143\u2013147 (2006).","journal-title":"J. Psychoactive Drugs"},{"key":"18645_CR33","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.addbeh.2005.08.005","volume":"31","author":"TFM ter Bogt","year":"2006","unstructured":"ter Bogt, T. F. M., Engels, R. C. M. E. & Dubas, J. S. Party people: Personality and MDMA use of house party visitors. Addict. Behav. 31, 1240\u20131244 (2006).","journal-title":"Addict. Behav."},{"key":"18645_CR34","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1038\/s41598-022-06580-2","volume":"12","author":"GM Jones","year":"2022","unstructured":"Jones, G. M. & Nock, M. K. Exploring protective associations between the use of classic psychedelics and cocaine use disorder: A population-based survey study. Sci. Rep. 12, 2574 (2022).","journal-title":"Sci. Rep."},{"key":"18645_CR35","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1038\/s41598-022-08085-4","volume":"12","author":"G Jones","year":"2022","unstructured":"Jones, G., Ricard, J. A., Lipson, J. & Nock, M. K. Associations between classic psychedelics and opioid use disorder in a nationally-representative US adult sample. Sci. Rep. 12, 4099 (2022).","journal-title":"Sci. Rep."},{"key":"18645_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016025","volume":"7","author":"E Argento","year":"2017","unstructured":"Argento, E. et al. Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting. BMJ Open 7, e016025 (2017).","journal-title":"BMJ Open"},{"key":"18645_CR37","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1177\/0269881118798610","volume":"32","author":"E Argento","year":"2018","unstructured":"Argento, E., Braschel, M., Walsh, Z., Socias, M. E. & Shannon, K. The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women. J. Psychopharmacol. 32, 1385\u20131391 (2018).","journal-title":"J. Psychopharmacol."},{"key":"18645_CR38","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","volume":"32","author":"R Carhart-Harris","year":"2018","unstructured":"Carhart-Harris, R. et al. Psychedelics and the essential importance of context. J. Psychopharmacol. 32, 725\u2013731 (2018).","journal-title":"J. Psychopharmacol."},{"key":"18645_CR39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/02791072.2002.10399954","volume":"34","author":"K McElrath","year":"2002","unstructured":"McElrath, K. & McEvoy, K. Negative experiences on Ecstasy: The role of drug, set and setting. J. Psychoactive Drugs 34, 199\u2013208 (2002).","journal-title":"J. Psychoactive Drugs"},{"key":"18645_CR40","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(17)30569-X","volume":"389","author":"ZD Bailey","year":"2017","unstructured":"Bailey, Z. D. et al. Structural racism and health inequities in the USA: Evidence and interventions. The Lancet 389, 1453\u20131463 (2017).","journal-title":"The Lancet"},{"key":"18645_CR41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1146\/annurev-publhealth-040218-043750","volume":"40","author":"DR Williams","year":"2019","unstructured":"Williams, D. R., Lawrence, J. & Davis, B. Racism and health: Evidence and needed research. Annu. Rev. Public Health 40, 105\u2013125 (2019).","journal-title":"Annu. Rev. Public Health"},{"key":"18645_CR42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1300\/J233v06n02_06","volume":"6","author":"SE McCabe","year":"2007","unstructured":"McCabe, S. E. et al. Race\/ethnicity and gender differences in drug use and abuse among college students. J. Ethn. Subst. Abuse 6, 75\u201395 (2007).","journal-title":"J. Ethn. Subst. Abuse"},{"key":"18645_CR43","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1353\/hpu.0.0323","volume":"21","author":"DP Scharff","year":"2010","unstructured":"Scharff, D. P. et al. More than tuskegee: Understanding mistrust about research participation. J. Health Care Poor Underserved 21, 879\u2013897 (2010).","journal-title":"J. Health Care Poor Underserved"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18645-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18645-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18645-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T23:07:48Z","timestamp":1665443268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18645-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["18645"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-18645-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]},"assertion":[{"value":"24 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16976"}}